Cefoperazone for empiric therapy in patients with impaired renal function

Area of Science:

• Infectious Diseases
• Nephrology
• Pharmacology

Background:

• Serious infections in patients with impaired renal function pose significant treatment challenges.
• Empirical antibiotic therapy is often necessary in critically ill patients with renal dysfunction.
• Cefoperazone is a third-generation cephalosporin with broad-spectrum activity.

Purpose of the Study:

• To evaluate the efficacy and safety of cefoperazone in treating serious infections in patients with impaired renal function.
• To assess the incidence of hypoprothrombinemia and its management with vitamin K.
• To determine cefoperazone serum concentrations in patients with varying degrees of renal and hepatic function.

Main Methods:

• Thirty-five patients with serious infections and impaired renal function received empirical cefoperazone (2-8 g/day).
• Infection types included sepsis, urinary infections, pneumonia, and intra-abdominal infections.
• Clinical and microbiologic outcomes, adverse events (hypoprothrombinemia), and serum concentrations were monitored.

Main Results:

• An overall clinical and microbiologic cure rate of 91.4% (32/35) was observed.
• Hypoprothrombinemia occurred in 18/28 patients not receiving prophylactic vitamin K, resolving with vitamin K treatment.
• Elevated cefoperazone serum concentrations were noted in patients with hepatic dysfunction and jaundice.

Conclusions:

• Cefoperazone demonstrates high efficacy in treating serious infections in patients with impaired renal function.
• Prophylactic vitamin K is recommended to prevent cefoperazone-induced hypoprothrombinemia in this population.
• Therapeutic drug monitoring may be beneficial for optimizing cefoperazone dosing in patients with renal and hepatic dysfunction.